ReviewBiomaterials science2022
Nanoparticle personalized biomolecular corona: implications of pre-existing conditions for immunomodulation and cancer.
Review in Biomaterials science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Lipid Nanoparticle Development in Practice: Challenges and Collective Insights.Pharmaceutical research · 2026Review
- Nature-Inspired Alternatives to PEG for Next-Generation Long-Circulating Nanocarriers.International journal of nanomedicine · 2026Review
- Evaluating the impact of chaotropic salts on protein corona formation on polyethylene glycol-b-polylactic acid polymersomes.Journal of colloid and interface science · 2025Article
- Therapeutic Implications of Biomolecular Corona on Lipid Nanoparticle-Based Gene Delivery Systems.Small science · 2025Article
- Lipid nanoparticles fromMolecular therapy. Methods & clinical development · 2025Article
- Microfluidics-generated PLA nanoparticles: impact of purification method on macrophage interactions, anti-inflammatory effects, biodistribution, and protein corona formation.RSC pharmaceutics · 2025Article
- Synergistic Potential of Nanomedicine in Prostate Cancer Immunotherapy: Breakthroughs and Prospects.International journal of nanomedicine · 2024Review
- Cell and biomaterial delivery strategies to induce immune tolerance.Advanced drug delivery reviews · 2023Review
- Excipient-Free Ionizable Polyester Nanoparticles for Lung-Selective and Innate Immune Cell Plasmid DNA and mRNA Transfection.ACS applied materials & interfaces · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Nanoparticles (NPs) have demonstrated great promise as immunotherapies for applications ranging from cancer, autoimmunity, and infectious disease. Upon encountering biological fluids, NPs rapidly adsorb biomolecules, forming the "biomolecular corona" (BC), and the altered character of NPs due to their newly acquired biological identity can impact their
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.